[Corrected 8/10/12, 7:30 pm. See below.] Thermo Fisher Scientific (NYSE: [[ticker:TMO]]), the Waltham, MA-based provider of lab tools and life sciences instruments, announced today that it has signed a definitive agreement to buy Canoga Park, CA-based One Lambda for $925 million. The deal is expected to close in fourth quarter of this year and to be immediately accretive. The company predicts it will add between $0.09 and $0.11 to Thermo Fisher’s 2013 adjusted earnings per share.
One Lambda develops diagnostics technology that enables organ transplant centers to determine the compatibility of donors and recipients and to detect antibodies that could lead to transplant rejection. A report from Bloomberg earlier this morning indicates that Thermo Fisher outbid several other parties for the company. The $925 million price tag includes a three-year retention plan for some employees, amounts payable to shareholders for noncompetition agreements, and a one-year earn-out provision tied to certain financial targets. [An earlier version incorrectly stated billion instead of million. We regret the error—Eds]
According to Thermo Fisher’s website, this is the company’s first acquisition of 2012. It follows a 2011 acquisition spree, which included its $3.5 billion purchase of the allergy diagnostics company Phadia, as well as acquisitions of companies such as TREK Diagnostic Systems, Sterilin, and Dionex.
